Prebalin

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Prebalin

Pregabalin: A Definition and Chemical Origin

The medicinal entity Prebalin is a trade name for the active ingredient Pregabalin, an orally administered pharmaceutical agent. Pregabalin is a synthetic compound structurally identified as (S)-3-(aminomethyl)-5-methylhexanoic acid, which is recognized as a chemical analogue of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA). The preparation is formulated as a single, standalone active component in various oral dosage forms, including hard capsules and tablets, and is typically a prescription-only medicine. This chemical origin places Pregabalin within the specific family of compounds known as Gabapentinoids.

What Pharmacological Class Does Pregabalin Belong To?

Pregabalin is officially categorized within the anticonvulsant and analgesic pharmacological classes, targeting neural hyperexcitability within the central nervous system. Its distinctive function is its ability to bind with high affinity to the alpha2delta subunit, an auxiliary site on voltage-gated calcium channels on nerve endings. Pharmacological profiles indicate that Pregabalin is a bioavailable compound primarily eliminated by renal excretion, a characteristic supported by its chemical properties and behavior within the body.

General Purpose: How Pregabalin Supports Nerve Function

The overall purpose of Pregabalin is to stabilize and modulate neuronal hyperexcitability, thereby reducing the flow of abnormal electrical signals and minimizing chronic nerve pain transmission. By acting as a moderator of neurotransmitter release, Pregabalin dampens the constant, overwhelming signaling that occurs in overstimulated or damaged nerves. This mechanism provides central nervous system modulation, making its general benefit centered on calming the nervous system to ease discomfort associated with persistent nerve signaling problems.

Regulatory References

  1. Pregabalin - StatPearls - NCBI Bookshelf - NIH

What side effects are possible with Prebalin?

Possible Side Effects and Safety Information

Adverse reactions associated with Pregabalin, the active ingredient in Prebalin, are formally categorized in regulatory documentation by frequency and the physiological system affected. The most frequently documented effects often impact the central nervous system, particularly during the initial phases of treatment or dose increases.

Frequency-Classified Adverse Reactions

Classification Examples of Documented Effects
Very Common (ge 10%) Dizziness and Somnolence (drowsiness)
Common (1-10%) Peripheral edema, Weight gain, Blurred vision, Ataxia (loss of coordination), and Dry mouth

Serious Adverse Reactions

Regulatory documents highlight the potential for certain severe reactions requiring immediate consideration. These include the occurrence of Angioedema (swelling of the face, mouth, or throat), severe Hypersensitivity Reactions, and a documented risk of Respiratory Depression, especially when used concurrently with other Central Nervous System (CNS) depressants like opioids. Consistent with the antiepileptic drug class, official labels note a potential for Suicidal Behavior and Ideation.

Population and Exposure Safety Notes

The medicine is primarily eliminated by the kidneys; therefore, the official label requires dose adjustment for individuals with renal impairment to prevent accumulation. Older adults may also require adjustments due to age-related decline in renal function. Furthermore, abrupt or rapid discontinuation of the medicine may lead to documented withdrawal symptoms, including insomnia, headache, and nausea, and is advised against in regulatory instructions.

Overdose and Emergency Response

Overdose and when to seek help

This section describes official information on Pregabalin overdose as documented in government regulatory sources.

Overdose Scope

Domain Official Regulatory Statement
Documented overdose presentations: Overexposure is documented to present with central nervous system effects, including a reduced state of consciousness (somnolence, dizziness), alongside confusional state, agitation, and restlessness [NIH/DailyMed].
Physiological systems affected (as stated in label): Primarily the Central Nervous System (CNS) and the Respiratory system, noting the risk of life-threatening respiratory compromise [FDA Label, FDA DSC].
Dose-related or exposure-related factors (if applicable): The greatest risk of severe toxicity, including coma and seizures, is associated with co-ingestion of other CNS depressants [FDA DSC].
Population-specific overdose notes (if applicable): Elderly patients and individuals with respiratory risk factors are explicitly noted to have an increased risk of serious breathing difficulties. Patients with reduced renal function have a higher risk of accumulation [FDA DSC].
Emergency-response statements (as written in official documents): General supportive care is required, including monitoring of vital signs. No specific antidote is known; however, hemodialysis can effectively remove the drug in severe intoxication [FDA Label].
When immediate medical help is required (label-derived phrasing only): Seek medical attention immediately is mandated for symptoms of serious breathing difficulties, such as extreme sleepiness, confusion, or unresponsiveness, or for swelling of the face, tongue, or throat (angioedema) [FDA DSC, FDA Label].

Resulting Overdose Structure

The official regulatory profile emphasizes the primary risks of overdose—CNS depression and life-threatening respiratory compromise—as the triggers for emergency help. Documentation confirms that no specific antidote is available, and therefore, management focuses on general supportive measures, including continuous monitoring of vital signs. The conditions for seeking urgent help are explicitly defined by the presence of severe neurological or respiratory signs, as stipulated in government guidance.

Therapeutic Uses of Prebalin

What Pregabalin Treats: Main Uses and Benefits

Pregabalin is generally used to address conditions characterized by periods of heightened symptoms, primarily targeting certain types of nerve-related distress and episodic neurological activity. The medication is commonly used when supportive symptom management is appropriate, particularly in contexts involving heightened systemic burden.

Pregabalin is applied across therapeutic domains including chronic neuropathic pain (such as diabetic peripheral neuropathy and postherpetic neuralgia), fibromyalgia, and as adjunctive therapy for partial-onset seizures in epilepsy. Furthermore, it is used for managing the symptoms of Generalized Anxiety Disorder (GAD) in adults.

This supportive role may contribute to easing the overall symptom burden during periods of heightened symptoms. By addressing symptom clusters that may become intense or disruptive, the medication may assist with maintaining functional stability when symptoms interfere with routine activities.

“This medication is considered relevant for easing symptoms associated with acute or episodic changes and supports general well-being during symptomatic phases.”


Quick Fact: Support for Symptoms related to Nerve Pain and Systemic Discomfort Pregabalin may assist with managing persistent discomfort like the constant burning, shooting, or stabbing sensations of chronic neuropathy and the widespread muscle pain and tenderness of fibromyalgia.

Eligibility and Restrictions for Use

Who can and cannot use Prebalin?

The population eligibility for this medicine is strictly defined by regulatory authorities based on age, physiological status, and underlying health conditions.

Eligibility Scope

The medicine is formally established for use in adults 18 years of age and older. Use is not recommended for the pediatric population, specifically children and adolescents under 18 years, as official regulatory data has not established safety and efficacy in this group. Furthermore, use is not recommended for women who are pregnant or are currently breastfeeding.

Absolute Non-Eligibility

The medicine is strictly contraindicated for any individual with a known hypersensitivity or severe allergic reaction to the active substance or to any of the inactive ingredients (excipients). Certain oral formulations also make the medicine contraindicated for patients with rare hereditary sugar intolerances, such as galactose intolerance or total lactase deficiency.

Conditional Eligibility and Restrictions

Eligibility becomes conditional for patients with impaired renal function, necessitating a dose adjustment determined by an assessment of kidney clearance. Older adults may also require this same review of renal function. Conditional use is additionally specified for those with congestive heart failure and patients with diabetes mellitus, with official documentation advising caution for these comorbidities.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Pregabalin carries a significant risk of pharmacodynamic interactions, which primarily involve enhancing the effects of other central nervous system (CNS) depressants. Concomitant use with medicines such as opioid pain relievers (e.g., oxycodone), anxiety medications (e.g., lorazepam), and alcohol (ethanol) can lead to additive impairment of cognitive and motor function. This combination also elevates the risk of severe respiratory depression, a potentially life-threatening condition, particularly in elderly patients or those with existing respiratory or neurological disease.

Mechanistic studies confirm that Pregabalin is negligibly metabolized and does not inhibit or induce major liver enzymes (Cytochrome P450 system). Consequently, it is not expected to cause or be subject to significant pharmacokinetic interactions with most medicines, including oral contraceptives and common antiepileptic drugs (e.g., carbamazepine, phenytoin, lamotrigine, valproic acid).

However, other specific caution points exist:

  • ACE Inhibitors: Co-administration may increase the risk of angioedema (swelling of the face, lips, tongue, or throat).
  • Thiazolidinedione Antidiabetic Agents: Combination use may cause an additive effect on weight gain and peripheral edema, potentially requiring adjustments to diabetes medication regimens.

Mechanism of Action

The active ingredient, Pregabalin, functions by modulating excessive electrical signaling in the nervous system through a specific molecular interaction, which alters the activity of overactive neural pathways.


Targeting the Alpha-2-Delta Subunit

This mechanism involves Pregabalin acting as a specific ligand that binds to the mathbfalpha 2delta subunit of Voltage-Gated Calcium Channels (VGCCs) found on presynaptic nerve terminals. This binding is a form of modulation that reduces the channel's function and availability, which initiates the core mechanistic cascade resulting in the molecule's physiological consequences.


Reducing Excitatory Neurotransmitter Release

Modulating the alpha 2delta subunit restricts the flow of calcium ions (mathrmCa^2+) into the nerve cell, a process vital for chemical communication. This resulting decrease in calcium influx directly leads to a reduction in the release of several key excitatory neurotransmitters, including glutamate and substance P, thereby altering the transmission dynamics.


Altering Pathological Neural Hyperexcitability

By limiting the release of these excitatory signals, Pregabalin alters the activity of neural circuits characterized by pathological hyperexcitability (excessive, sustained firing). This alteration of signal transmission results in a reduction of sustained activity within targeted nerve pathways, which contributes to the molecule’s overall physiological profile.

Dosage and Administration Information

Official Administration Guidelines

Pregabalin (the active ingredient in Prebalin) is a medicine for oral use only and is primarily available in Immediate-Release (IR) capsules and solutions, and Extended-Release (ER) tablets. The official usage protocol mandates a systematic approach to dosing.

Standard Dosing Protocol

Treatment typically begins with a low starting dose of 150 mg/day administered in two or three divided doses (for IR forms). The dosage is then titrated upward over a period of at least one week to reach a standard maintenance range, which for most adult indications extends up to a maximum of 600 mg/day. The total daily dose is divided into multiple administrations for IR forms, while ER tablets are administered once daily.

Feature Official Regulatory Instruction
Timing in Relation to Meals Immediate-Release Forms: May be taken with or without food. Extended-Release Tablets: Must be taken once daily after an evening meal.
Renal Function Adjustment Dose must be reduced and individualized in patients with impaired renal function because the medicine is primarily eliminated by the kidneys. Hemodialysis patients require a supplementary dose following each treatment.
Discontinuation If treatment must be stopped, the dose should be tapered gradually over a minimum period of one week regardless of the indication.

These official instructions define a protocol that is initiated with a controlled low dose, adjusted based on kidney clearance, and requires gradual tapering upon cessation to ensure compliance with regulatory standards.

Recent Clinical Evidence

Recent Clinical Evidence

The evaluation of Prebalin has focused on its potential role in managing chronic pain conditions, including neuropathic pain and fibromyalgia.

Phase 3 Trial Data Summary

Mechanism of Action Research

Research investigated the mechanism of action, which was used to inform the design of the clinical studies. Studies have explored the compound's binding to the alpha-2-delta subunit of voltage-gated calcium channels in the central nervous system.

Efficacy and Symptom Measures

Studies have evaluated the effect on symptoms in cohorts of participants diagnosed with various neuropathic conditions. Key findings reported that the compound was associated with a reduction in pain compared to control groups in several trials of varying durations (typically 4 to 15 weeks).

Outcome Measured Finding Reported (vs. Placebo)
Pain Intensity Scores Indicated statistically significant differences
Pain-Related Sleep Interference Associated with improvements
Patient Global Impression of Change Associated with improvements

Safety Profile Findings

Across the clinical development program, the adverse event profile collected was consistent with the pharmacological class. The most frequent events reported were dizziness and somnolence, which often appeared early in the course of treatment. The incidence of these events was generally dose-related.

Long-Term Follow-up and Quality of Life

Long-term, open-label studies extending up to 53 weeks were conducted to assess safety and tolerability. Research examining the combination of Prebalin with existing standard-of-care medications indicated differences across several domains of health-related quality of life questionnaires, including general activity and mood. These findings reported favorable long-term findings regarding tolerability and maintenance of effect over the study duration.

Frequently Asked Questions (FAQ)

Common questions about Prebalin (FAQ)


Q: How quickly should I expect to feel a difference after starting Prebalin?

Clinical studies for some conditions (e.g., spinal cord injury) indicated that some participants reported differences in pain as early as the first week of treatment. However, the time required to feel the full effect may take longer and can vary based on the individual and the specific condition being addressed.


Q: What happens if I forget to take a dose of Prebalin?

Regulatory guidance describes a protocol where a missed dose may be taken as soon as it is remembered. However, if it is almost time for the next scheduled dose, the guidance specifies that the missed dose should be skipped. The guidance also advises continuing the regular schedule and specifies that taking two doses at once to compensate for a missed dose is not recommended.


Q: Is Prebalin considered a controlled substance in many countries?

The active ingredient in Prebalin, Pregabalin, is formally classified as a Schedule V controlled substance by the U.S. Drug Enforcement Administration (DEA). This classification is applied due to the drug's documented potential for misuse and reports of patients experiencing feelings of euphoria.


Q: What are the official approved uses of Prebalin?

Regulatory bodies, such as the U.S. FDA, have approved the use of Pregabalin for several conditions in adults. These official indications include the management of specific types of neuropathic pain (such as pain from diabetic peripheral neuropathy, postherpetic neuralgia, and spinal cord injury) and for treating fibromyalgia. It is also approved as an adjunctive treatment for partial-onset seizures in adults with epilepsy.


Q: If I am taking vitamins or supplements, could they interact with Prebalin?

Official guidance includes warnings that certain herbal preparations and supplements can have a central nervous system (CNS) depressant effect. This effect involves sedation or drowsiness. Because Prebalin also acts on the CNS, these combined effects may be increased. Regulatory agencies describe that caution is necessary when the medicine is used concurrently with these types of supplements.


Q: Can I take non-prescription pain relievers with Prebalin?

Official product information indicates that the active ingredient is not expected to cause significant pharmacokinetic (drug processing) interactions with most medicines. However, official documentation describes the need for caution when the medicine is combined with any over-the-counter (OTC) medicine that affects the central nervous system, such as some antihistamines, due to the potential for combined sedation or drowsiness.


Q: Does Prebalin affect laboratory test results for other conditions?

There is no broad regulatory statement that Prebalin interferes with the results of most routine laboratory tests for other health conditions. However, the medicine itself may be monitored by specific tests (such as serum concentrations) in the context of assessing kidney function.


Q: Can Prebalin be crushed, split, or chewed, or should it be swallowed whole?

The official instructions for administration vary depending on the product formulation. Specifically, Extended-Release (ER) tablets are designated to be swallowed whole and are described as unsuitable for splitting, crushing, or chewing. This is done to ensure the medicine is released slowly over time as intended.


Q: Is it possible for Prebalin to interact with herbal remedies like St. John's Wort?

Regulatory guidance includes a general warning that certain herbal preparations designed to relax or calm can have a central nervous system (CNS) depressant effect. When taken with Prebalin, which also acts as a CNS depressant, there is a risk of increased sedation and drowsiness. Official information indicates that caution is necessary in this context.


Q: How do doctors monitor a patient’s progress while they are taking Prebalin?

The official protocol includes checking a patient's progress at regular visits, especially during the first few months, to review the patient’s status. Depending on the patient’s health profile, blood tests may also be needed to check for unwanted effects, particularly those concerning kidney function.


Q: What should a patient do if they experience a severe side effect from Prebalin?

Regulatory documents emphasize that certain serious reactions require immediate attention. Severe side effects, such as swelling of the face, throat, or lips (known as angioedema), difficulty breathing, or severe confusion are serious events that necessitate immediate medical attention.


Q: What are the facts about Prebalin and potential fertility issues?

Official safety updates describe the recommendation that men and women use effective contraception during treatment with Prebalin. This measure is based on preclinical studies that have shown the potential for impaired fertility in male subjects.


Q: Is it necessary to have routine blood work done while taking Prebalin?

Official guidance does not mandate blanket routine blood work for all patients. However, regulatory documents affirm that blood tests may be needed to check for unwanted effects, especially in patients who have kidney disease or other conditions that might affect how the medicine is cleared from the body.


Q: Are there any reports about Prebalin causing hair loss?

While not frequently listed as a common effect in patient information, the full regulatory prescribing information does contain mentions of alopecia (the medical term for hair loss) in the section covering post-marketing adverse reactions reported by patients.


Q: Can Prebalin affect my ability to concentrate or operate machinery?

The active ingredient can cause central nervous system effects such as dizziness, drowsiness (somnolence), and loss of coordination (ataxia). Because of this, official sources warn that this medicine may impair the ability to drive or operate machinery. Official sources describe that caution is warranted until an individual understands how the medicine affects them.


Q: Is there any research on Prebalin and mood changes or feelings of anxiety?

Clinical research has examined the effect on quality of life, which includes reports of changes in mood. Additionally, regulatory documents highlight a documented risk of suicidal behavior and ideation consistent with the antiepileptic drug class, requiring careful monitoring.


Q: Why do some people experience dizziness when they first start taking Prebalin?

Dizziness is documented as a very common side effect that frequently appears early in the course of treatment, often when the dose is being adjusted. This effect is related to the medicine's primary mechanism of action: modulating signaling pathways in the central nervous system.


Q: How does the way Prebalin is processed in the body relate to its side effects?

Official information states that the medicine is primarily eliminated by the kidneys and is negligibly processed by the liver. Because of this, patients with reduced kidney function must have their dose lowered. This reduction is necessary to manage the risk of side effects associated with accumulation, such as sedation.


Q: What are the main things doctors consider when deciding if Prebalin is right for a patient?

Official documentation defines several key eligibility and restriction factors. These include the patient's age (established for use in adults 18 and over), the presence of kidney impairment (which requires dose adjustment), and existing conditions such as congestive heart failure or diabetes mellitus that necessitate caution.


Q: Do regulatory bodies classify Prebalin as having a potential for misuse?

Official regulatory warnings acknowledge that the medicine has a potential for misuse. This risk is reflected in its classification as a Schedule V controlled substance and is the reason official guidance mandates that the medication be stored securely, out of the sight and reach of children.


Q: Are headaches a common side effect when taking Prebalin?

Headaches are not listed among the official very common or common side effects experienced during the course of continuous treatment. However, regulatory documents do specifically list headache as one of the documented symptoms that may occur if the medicine is discontinued too rapidly.


Q: What are the official warnings about driving while taking Prebalin?

Official warnings explicitly state that the medicine can cause central nervous system effects, including dizziness, drowsiness (somnolence), and loss of coordination (ataxia). These documented effects may impair a patient's ability to drive or operate complex machinery. Official warnings describe that caution is warranted.


Q: Does the efficacy of Prebalin change over time in a single patient?

Regulatory and clinical studies have examined the drug's long-term use and maintenance of effect. Findings from long-term, open-label studies extending up to a year generally indicate maintenance of the effect over the study duration. The data from these long-term studies did not demonstrate a universal loss of effect.


Q: Can older adults expect different results or side effects from Prebalin?

Official documents note that older adults may require different management, primarily due to the age-related decline in kidney function. Since the drug is cleared by the kidneys, older adults frequently require an adjustment to their dose to prevent drug accumulation, which could increase the risk of certain side effects.


Q: How do the different forms of Prebalin (e.g., capsules, liquid) compare?

Prebalin is available in different oral dosage forms, including capsules, tablets, and a liquid solution. The key difference relates to administration protocol: Immediate-Release forms are taken in divided doses, while Extended-Release tablets are taken once daily after an evening meal.

How should Prebalin be stored and disposed of?

How to Store and Dispose of Pregabalin

The official labeling mandates specific requirements for the storage and disposal of pregabalin to maintain product stability and ensure safety.


Storage Conditions

  • Temperature and Protection: The medication must be stored at Controlled Room Temperature, typically 25 C (77 F), with permitted excursions between 15 C and 30 C (59 F and 86 F). It must be kept away from excess heat and moisture and protected from light.
  • Packaging: Pregabalin must be stored in its original container, which should be kept tightly closed.
  • Child Safety: Due to its potential for misuse, the medication is required to be stored out of the sight and reach of children in a secure location.

Disposal Requirements

  • General Rule: Unused or expired medication must be disposed of in accordance with local requirements.
  • Environmental Protection: It is explicitly stated that disposal should avoid release to the environment and that the product should not be emptied into drains or wastewater systems.
  • Discarding: If an official take-back program is unavailable, certain government guidelines permit disposing of unused medicine in household trash after mixing it with an unappealing substance and sealing it.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Prebalin found in:

A-Z Index: